International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
Condition(s) studied
Study summary
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD.
The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its recurrence. This observational study will be prospective and retrospective in its recruitment and will collect clinical information to better understand the natural history and prognosis for SCAD.
Eligibility
Primary outcome measure(s)
- Descriptive Data — Continuous time frame following index event for an average of 3 years from study contact date
Participant demographic, historical, clinical characteristics, and treatment data - Clinical Outcomes — Continuous time frame following index event for an average of 3 years from study contact date
Prospectively collected long-term outcomes including recurrent myocardial infarction, hospitalization, heart failure, stroke or transient ischemic attack, arrhythmia, and all cause mortality - Psychosocial Outcomes — Continuous time frame following index event for an average of 3 years from study contact date
Prospectively collected data on participant's mental health using validated questionnaires
Trial sites (31)
| Facility | City | Region | Status |
|---|---|---|---|
| Cedars Sinai | Los Angeles | California | |
| UCLA (University of California, Los Angeles) | Los Angeles | California | |
| Kaiser Permanente Northern California | San Francisco | California | |
| University of Colorado | Aurora | Colorado | |
| Hartford Hospital | Hartford | Connecticut | |
| University of South Florida | Tampa | Florida | |
| Emory Healthcare System | Atlanta | Georgia | |
| Northwestern Medicine | Chicago | Illinois | |
| University of Kentucky | Lexington | Kentucky | |
| Johns Hopkins | Baltimore | Maryland | |
| Massachusetts General Hospital | Boston | Massachusetts | |
| St. Luke's Mid America | Kansas City | Missouri | |
| Washington University | St Louis | Missouri | |
| Dartmouth-Hitchcock | Lebanon | New Hampshire | |
| Catholic Medical Center | Manchester | New Hampshire | |
| Mount Sinai | New York | New York | |
| Columbia University Medical Center | New York | New York | |
| Atrium Health Sanger Heart and Vascular Institute | Charlotte | North Carolina | |
| University Hospitals--Case Western | Cleveland | Ohio | |
| Oklahoma Heart | Oklahoma City | Oklahoma | |
| Providence | Portland | Oregon | |
| University of Pennsylvania | Philadelphia | Pennsylvania | |
| Allegheny General Hospital, Allegheny Health Network | Pittsburgh | Pennsylvania | |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | |
| Vanderbilt University Medical Center | Nashville | Tennessee | |
| UT Southwestern | Dallas | Texas | |
| Intermountain | Murray | Utah | |
| University of Virginia | Charlottesville | Virginia | |
| Inova Heart & Vascular Institute | Fairfax | Virginia | |
| University of Washington Medicine | Seattle | Washington | |
| Victor Chang Cardiac Research Institute | Darlinghurst | New South Wales |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04496687 on ClinicalTrials.gov ↗ ← All trials in Australia